Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...

Asthma and atopic dermatitis are chronic inflammatory diseases of the airways and the skin, respectively, which affect hundreds of millions of children and adults globally. Most patients with asthma ...

In a video interview with Healio, Benjamin N. Ungar, MD, discussed the risk factors of atopic dermatitis and the comorbidities associated with the condition.

Learn how ultrafine bubble showers can improve eczema symptoms by reducing inflammation and enhancing skin barrier proteins.

PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

In this video, Robert Sidbury MD, MPH, division head of dermatology at Seattle Children’s Hospital and professor in the department of pediatrics at University of Washington School of Medicine, ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Bubble baths might be soothing soaks, but bubble showers could be the next thing in keeping the skin clean. An Osaka ...

The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

A medical research team has confirmed that ultrafine bubble showers significantly suppress inflammation in mice with atopic dermatitis due to external factors.

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent ...